Impel Neuropharma Inc - ESG Rating & Company Profile powered by AI
The Disclosure score includes 17 UN Sustainable Development Goals including: 'Affordable & Clean Energy', 'Sustainable Cities & Communities' and 'Life on Land'. Detailed ESG assessment of Impel Neuropharma Inc can be accessed by registering for free. The page is a zero-cost ESG analysis covering Impel Neuropharma Inc.
Impel Neuropharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 2.0, social score of 1.6 and governance score of 1.6.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | Impel Neuropharma Inc | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Impel Neuropharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Impel Neuropharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Impel Neuropharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Impel Neuropharma Inc offer flexible work?
Sign up for free to unlockDoes Impel Neuropharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Impel Neuropharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Impel Neuropharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose water use targets?
Sign up for free to unlockDoes Impel Neuropharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Impel Neuropharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Impel Neuropharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Impel Neuropharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Impel Neuropharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Impel Neuropharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Impel Neuropharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose its waste policy?
Sign up for free to unlockDoes Impel Neuropharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose energy use targets?
Sign up for free to unlockDoes Impel Neuropharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Impel Neuropharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Impel Neuropharma Inc
These potential risks are based on the size, segment and geographies of the company.
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.